Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer - ScienceDirect
SGO on Twitter: "Improved overall survival with olaparib maintenance was clear - even when pts in the placebo group were treated with #PARPi in a later line - important information for sequencing
392 Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: subgroup analysis by risk in the phase III solo1 study | International Journal of Gynecologic Cancer
Real-World Use and Outcomes of Olaparib: a Population-Based Cohort Study | SpringerLink
Lynparza extended survival of ovarian cancer patients' < Pharma < Article - KBR
Long-term survival benefits with olaparib in ovarian cancer
FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer - Arora - 2021 - The Oncologist - Wiley Online Library
5-year follow-up data from the SOLO-1 trial with analysis of the information up to March 5, 2020 were highlighted at ESMO 2020 - Onco Americas
Cancers | Free Full-Text | Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer
SOLO1: Olaparib Maintenance Continues to Provide Clinical Benefit at 7 Years - Cancer Therapy Advisor
Comparison of survival between overall BRCA mutation and BRCA wild-type... | Download Scientific Diagram
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy | British Journal of Cancer
ARIEL4 Confirms Rucaparib's Efficacy in Recurrent, BRCA-Mutated Ovarian Cancer: Does It Tell Us Anything New? - The ASCO Post
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial - Annals of Oncology
Projection of long-term overall survival among patients with newly diagnosed advanced ovarian cancer and a <em>BRCA1/2</em> mutation
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3
Survival Rates in Stage IV Melanoma Patients Treated Immunotherapy and Radiation Differ According to Age and Radiation Treatment
SOLO-1 Phase 3 Trial – Efficacy of LYNPARZA® (olaparib) for BRCAm Advanced Ovarian Cancer
SOLO-1 Phase 3 Trial Demonstrates LYNPARZA® (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer | Business Wire
Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care? | Future Oncology
SOLO-1 Phase 3 Trial – Efficacy of LYNPARZA® (olaparib) for BRCAm Advanced Ovarian Cancer
